Back to search results

Electronic Symptom Monitoring for Thoracic Cancer Patients

This study is testing an electronic symptom monitoring program for people with thoracic cancer (cancer in the chest). The program aims to help patients and their caregivers track symptoms and easily refer themselves to palliative care (specialized medical care for people with serious illnesses). Researchers want to see how often people use the program to log symptoms and if it helps them get palliative care sooner. You can join if you are at least 18 years old, have any stage or type of thoracic cancer, and have had at least two visits at the Ohio State University Comprehensive Cancer Center Thoracic Oncology Clinic. The study is looking to enroll 157 participants, but its current status is unclear.

Study design
This is an interventional study, meaning participants will receive a specific intervention. It plans to enroll 157 participants.
What's involved
You and your caregiver will use an electronic symptom monitoring program to log symptoms once a week for 24 weeks. You will also watch a video and review educational materials before starting the program.
Compensation
Not stated in the trial record.
Follow-up
After completing the study intervention, participants will be followed up for up to 2 years.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06396598

Electronic Symptom Monitoring Program for Triggered Palliative Referrals in Patients With Thoracic Cancer

Active, Not Recruiting
NAAges 18+InterventionalSupportive care
Ohio State University Comprehensive Cancer Center
~157 participants
Updated 2026-06-15 on ClinicalTrials.gov
What's tested:Educational ActivityElectronic Health Record ReviewInternet-Based InterventionMedia InterventionSurvey Administration

At a glance

Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Frequency of symptom logging
Measured over At 6 months after enrollment
+3 more outcomes measured

Conditions

Malignant Thoracic Neoplasm

Explore related trials

Lung Non-Small Cell CarcinomaLung Small Cell CarcinomaMesothelial NeoplasmThoracic NeoplasmThymus Carcinoma

Where it's being run

1 sites across 1 states
Ohio1

Study leadership

  • Julia L Agne, MD · PRINCIPAL_INVESTIGATOR · Ohio State University Comprehensive Cancer Center

Who to contact

This trial hasn't published a contact. View it on ClinicalTrials.gov

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

PATIENTS: Age ≥ 18 years
PATIENTS: Diagnosed with any stage (1-4) or type (non-small cell lung cancer, small cell lung cancer, mesothelioma, thymic carcinoma) of thoracic malignancy
PATIENTS: ≥ 2 visits at the Ohio State University Comprehensive Cancer Center (OSUCCC) Thoracic Oncology Clinic
PATIENTS: Study enrollment within 12 weeks of initial Thoracic Medical Oncology appointment
PATIENTS: Ability to understand and willingness to sign an informed consent document (or indicate approval or disapproval by another means)
PATIENTS: Ability to read and understand English
PATIENTS: Access to a device with email or text messaging capability
CAREGIVERS: Age ≥ 18 years
CAREGIVERS: Identified by patient participant as primary caregiver
CAREGIVERS: Corresponding patient participant has consented to participate in the study
CAREGIVERS: Ability to understand and willingness to sign an informed consent document (or indicate approval or disapproval by another means)
CAREGIVERS: Ability to read and understand English
CAREGIVERS: Access to a device with email or text messaging capability

Exclusion

PATIENTS: Patients who have been previously referred to ambulatory palliative care are excluded from participation
PATIENTS: Prisoners are excluded from participation
PATIENTS: Pregnant patients are excluded from participation
PATIENTS: Patients who lack capacity for medical decision-making as determined by their primary oncologist are excluded from participation

What this trial measures

  • Frequency of symptom loggingAt 6 months after enrollment

    Will estimate that ≥ 50% of patient participants will log symptoms at least monthly through the remote electronic symptom monitoring program.

  • Proportion of patients enrolled (Feasibility)At enrollment and 3 months

    Descriptive statistics will include study enrollment rates (eligible vs. ineligible participants, consented vs. refused), completion rate of weekly symptom monitoring (patient vs. caregiver by proxy), and person requesting palliative care services (patient vs. caregiver by proxy vs. medical provider), if applicable. Will be considered feasible if within 20% of target enrollment.

  • Symptom scores and Palliative Referral AssociationAt enrollment and 3 months and 6 months

    Symptom scores (Edmonton Symptom Assessment Scale revised with Constipation and Sleep \[ESAS-r-CS\]) reported by patients and caregivers will be tracked and their association with palliative care referral, if applicable, will be assessed.

  • Patient and Caregiver Symptom Reporting CongruencyAt enrollment and 3 months and 6 months

    Descriptive statistics will be used to assess for congruency between patient and proxy-reported symptom assessments. Patients' oncologic treatment (chemotherapy, immunotherapy, radiation therapy, surgery) will be abstracted from the electronic medical record (EMR) at the time of each ESAS-r-CS survey completed by either the patient or caregiver by proxy.